Clinical pathological characteristics and prognostic analysis of diabetic women with luminal subtype breast cancer View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

2014-03

AUTHORS

Yuanting Xiao, Sheng Zhang, Guofang Hou, Xiaobei Zhang, Xiaomeng Hao, Jin Zhang

ABSTRACT

This study selected luminal-type breast cancer patients as the study subjects. The patients were divided into groups according to the presence of diabetes and the types of medication used, and the patients' clinicopathological characteristics and prognostic indicators were explored. A total of 5,785 patients with luminal-type breast cancer admitted to Tianjin Medical University Cancer Institute and Hospital between January 2002 and December 2006 were selected as the study subjects. The subjects included 680 breast cancer patients with diabetes and 5,105 breast cancer patients without diabetes. The patients were divided into Luminal A, Luminal B (high ki67), and Luminal B (her-2/neu+) subtypes. Each subtype was further divided into a metformin group, a non-metformin group, and a nondiabetic group. The research indicators included breast cancer mortality, age, body mass index (BMI), amenorrhea, the presence of cardiovascular and cerebrovascular disease, pathological stage, pathological type, lymph node involvement, vessel carcinoma embolus, and the chemotherapy and endocrine regimen. A Kaplan-Meier analysis was conducted to analyze the differences in breast cancer mortality rates among the groups. The Cox proportional hazard model was adopted to detect independent factors related to prognosis. Kaplan-Meier univariate analysis showed that for the Luminal A, Luminal B (high ki67), and Luminal B (her-2/neu+) subtypes, the cancer-specific mortality rates differed significantly among the metformin, non-metformin, and nondiabetic groups. The 5-year survival rates were 94%, 82%, and 91% (P = 0.002); 93.5%, 81%, and 89% (P < 0.001); and 84%, 77%, and 83% (P = 0.035) for the subtypes within each group, respectively. Cox regression multivariate analysis showed that compared with the metformin group, all three subtypes of the, the non-metformin group showed poorer prognosis (hazard ratio [HR], 3.579; 95% confidence interval [CI], 1.506-8.506 [P = 0.004]; HR, 3.232; 95% CI, 1.839-5.678 [P < 0.001]; HR, 2.034; 95% CI,1.019-4.059 [P = 0.044] for Luminal A, Luminal B (high ki67), and Luminal B (her-2/neu+, respectively). Compared with the metformin group, the diabetic group showed poorer prognosis only for the Luminal B (high ki67) subtype (HR, 1.762; 95% CI, 1.033-3.005 [P = 0.038]). In addition, for the Luminal A, Luminal B (high ki67), and Luminal B (her-2/neu+) subgroups, there was a higher proportion of elderly patients (P < 0.001) and postmenopausal patients (P < 0.001) in the metformin and non-metformin groups than in the nondiabetic group. Moreover, the probability of having cardiovascular and cerebrovascular disease was also higher (P < 0.001) in the metformin and non-metformin groups. For the Luminal B (high ki67) and Luminal B (her-2/neu +) subgroups, there was a higher proportion of obese patients in the metformin and non-metformin groups (P < 0.001). In terms of clinical characteristics, for the Luminal B (high ki67) subtype, the proportion of patients with invasive ductal carcinoma was lower in the non-metformin group than in the other two groups (P = 0.001). In both the metformin and non-metformin groups, the proportion of T3/4 patients was higher (P < 0.001), the proportion of patients with lymph node metastasis was higher (P = 0.001), and the proportion of patients with vessel carcinoma embolus was higher (P = 0.001) compared with the nondiabetic group. In conclusion, compared with the metformin group, the non-metformin group had a poorer prognosis for all subtypes of luminal breast cancer. In the diabetic group, only patients with the Luminal B (high ki67) subtype exhibited a poorer prognosis. Therefore, different diabetes medication may have a different impact on the prognosis of different subtypes of luminal breast cancer. More... »

PAGES

2035-2045

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/s13277-013-1270-5

DOI

http://dx.doi.org/10.1007/s13277-013-1270-5

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1048730426

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/24096546


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1112", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Oncology and Carcinogenesis", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Adult", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Breast Neoplasms", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Diabetes Mellitus, Type 2", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Female", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Hypoglycemic Agents", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Kaplan-Meier Estimate", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Metformin", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Middle Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Prognosis", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Proportional Hazards Models", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "name": [
            "Surgical Department, Tianhe Hospital, Tianjin, China"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Xiao", 
        "givenName": "Yuanting", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Tianjin Medical University Cancer Institute and Hospital", 
          "id": "https://www.grid.ac/institutes/grid.411918.4", 
          "name": [
            "3rd Department of Breast Cancer, China Tianjin Breast Cancer Prevention, Treatment and Research Center, Tianjin Medical University Cancer Institute and Hospital; National Clinical Research Center of Cancer, West Beihuanhu Road, 300060, Tianjin, China", 
            "Key Laboratory of Breast Cancer Prevention and Therapy of Ministry of Education, Tianjin, China", 
            "Key Laboratory of Cancer Prevention and Therapy, Tianjin, China"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Zhang", 
        "givenName": "Sheng", 
        "id": "sg:person.01250560002.28", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01250560002.28"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Tianjin Medical University Cancer Institute and Hospital", 
          "id": "https://www.grid.ac/institutes/grid.411918.4", 
          "name": [
            "3rd Department of Breast Cancer, China Tianjin Breast Cancer Prevention, Treatment and Research Center, Tianjin Medical University Cancer Institute and Hospital; National Clinical Research Center of Cancer, West Beihuanhu Road, 300060, Tianjin, China", 
            "Key Laboratory of Breast Cancer Prevention and Therapy of Ministry of Education, Tianjin, China", 
            "Key Laboratory of Cancer Prevention and Therapy, Tianjin, China"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Hou", 
        "givenName": "Guofang", 
        "id": "sg:person.01140643410.19", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01140643410.19"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Tianjin Medical University Cancer Institute and Hospital", 
          "id": "https://www.grid.ac/institutes/grid.411918.4", 
          "name": [
            "3rd Department of Breast Cancer, China Tianjin Breast Cancer Prevention, Treatment and Research Center, Tianjin Medical University Cancer Institute and Hospital; National Clinical Research Center of Cancer, West Beihuanhu Road, 300060, Tianjin, China", 
            "Key Laboratory of Breast Cancer Prevention and Therapy of Ministry of Education, Tianjin, China", 
            "Key Laboratory of Cancer Prevention and Therapy, Tianjin, China"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Zhang", 
        "givenName": "Xiaobei", 
        "id": "sg:person.0605031045.15", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0605031045.15"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Tianjin Medical University Cancer Institute and Hospital", 
          "id": "https://www.grid.ac/institutes/grid.411918.4", 
          "name": [
            "3rd Department of Breast Cancer, China Tianjin Breast Cancer Prevention, Treatment and Research Center, Tianjin Medical University Cancer Institute and Hospital; National Clinical Research Center of Cancer, West Beihuanhu Road, 300060, Tianjin, China", 
            "Key Laboratory of Breast Cancer Prevention and Therapy of Ministry of Education, Tianjin, China", 
            "Key Laboratory of Cancer Prevention and Therapy, Tianjin, China"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Hao", 
        "givenName": "Xiaomeng", 
        "id": "sg:person.01207031500.94", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01207031500.94"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Tianjin Medical University Cancer Institute and Hospital", 
          "id": "https://www.grid.ac/institutes/grid.411918.4", 
          "name": [
            "3rd Department of Breast Cancer, China Tianjin Breast Cancer Prevention, Treatment and Research Center, Tianjin Medical University Cancer Institute and Hospital; National Clinical Research Center of Cancer, West Beihuanhu Road, 300060, Tianjin, China", 
            "Key Laboratory of Breast Cancer Prevention and Therapy of Ministry of Education, Tianjin, China", 
            "Key Laboratory of Cancer Prevention and Therapy, Tianjin, China"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Zhang", 
        "givenName": "Jin", 
        "id": "sg:person.01240745050.60", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01240745050.60"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "https://doi.org/10.1016/j.diabres.2011.10.029", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1001437964"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s11670-012-0279-4", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1006388691", 
          "https://doi.org/10.1007/s11670-012-0279-4"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.steroids.2011.02.041", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1006914612"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/nrc3215", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1007018896", 
          "https://doi.org/10.1038/nrc3215"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1002/cncr.26439", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1007397922"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1111/j.1349-7006.2008.01053.x", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1008231897"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s1535-6108(02)00055-7", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1008635409"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1093/annonc/mdr534", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1011989210"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1073/pnas.1221055110", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1015828667"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s12032-011-0109-4", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1017161682", 
          "https://doi.org/10.1007/s12032-011-0109-4"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s10549-010-0990-0", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1022806761", 
          "https://doi.org/10.1007/s10549-010-0990-0"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s10549-010-0990-0", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1022806761", 
          "https://doi.org/10.1007/s10549-010-0990-0"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2009.27.3011", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1023678279"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1111/j.1467-789x.2011.00917.x", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1026394639"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s10549-012-2339-3", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1026751832", 
          "https://doi.org/10.1007/s10549-012-2339-3"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1158/0008-5472.can-07-2310", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1027138181"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.2337/dc08-2175", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1028017606"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1126/science.1092952", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1028575709"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1634/theoncologist.2011-0412", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1029603059"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1634/theoncologist.2010-0206", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1030560624"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1158/1940-6207.capr-08-0081", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1036462269"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1146/annurev-nutr-071811-150713", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1037521943"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1073/pnas.73.12.4536", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1037611161"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1056/nejmoa021423", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1041007839"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s10911-008-9097-1", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1041148032", 
          "https://doi.org/10.1007/s10911-008-9097-1"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1371/journal.pone.0051446", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1042829178"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1093/annonc/mdt224", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1042946743"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2009.19.6410", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1044475739"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1111/j.1749-6632.2012.06750.x", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1048083141"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s10552-012-0057-0", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1052280600", 
          "https://doi.org/10.1007/s10552-012-0057-0"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.4161/cc.8.1.7499", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1072299977"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1078589901", 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.3978/j.issn.2072-1439.2012.10.17", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1078655931"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.3978/j.issn.2072-1439.2012.10.17", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1078655931"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.3978/j.issn.1000-9604.2012.11.03", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1078680423"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.3978/j.issn.2072-1439.2013.05.24", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1078751548"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1080781104", 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2014-03", 
    "datePublishedReg": "2014-03-01", 
    "description": "This study selected luminal-type breast cancer patients as the study subjects. The patients were divided into groups according to the presence of diabetes and the types of medication used, and the patients' clinicopathological characteristics and prognostic indicators were explored. A total of 5,785 patients with luminal-type breast cancer admitted to Tianjin Medical University Cancer Institute and Hospital between January 2002 and December 2006 were selected as the study subjects. The subjects included 680 breast cancer patients with diabetes and 5,105 breast cancer patients without diabetes. The patients were divided into Luminal A, Luminal B (high ki67), and Luminal B (her-2/neu+) subtypes. Each subtype was further divided into a metformin group, a non-metformin group, and a nondiabetic group. The research indicators included breast cancer mortality, age, body mass index (BMI), amenorrhea, the presence of cardiovascular and cerebrovascular disease, pathological stage, pathological type, lymph node involvement, vessel carcinoma embolus, and the chemotherapy and endocrine regimen. A Kaplan-Meier analysis was conducted to analyze the differences in breast cancer mortality rates among the groups. The Cox proportional hazard model was adopted to detect independent factors related to prognosis. Kaplan-Meier univariate analysis showed that for the Luminal A, Luminal B (high ki67), and Luminal B (her-2/neu+) subtypes, the cancer-specific mortality rates differed significantly among the metformin, non-metformin, and nondiabetic groups. The 5-year survival rates were 94%, 82%, and 91% (P\u2009=\u20090.002); 93.5%, 81%, and 89% (P\u2009<\u20090.001); and 84%, 77%, and 83% (P\u2009=\u20090.035) for the subtypes within each group, respectively. Cox regression multivariate analysis showed that compared with the metformin group, all three subtypes of the, the non-metformin group showed poorer prognosis (hazard ratio [HR], 3.579; 95% confidence interval [CI], 1.506-8.506 [P\u2009=\u20090.004]; HR, 3.232; 95% CI, 1.839-5.678 [P\u2009<\u20090.001]; HR, 2.034; 95% CI,1.019-4.059 [P\u2009=\u20090.044] for Luminal A, Luminal B (high ki67), and Luminal B (her-2/neu+, respectively). Compared with the metformin group, the diabetic group showed poorer prognosis only for the Luminal B (high ki67) subtype (HR, 1.762; 95% CI, 1.033-3.005 [P\u2009=\u20090.038]). In addition, for the Luminal A, Luminal B (high ki67), and Luminal B (her-2/neu+) subgroups, there was a higher proportion of elderly patients (P\u2009<\u20090.001) and postmenopausal patients (P\u2009<\u20090.001) in the metformin and non-metformin groups than in the nondiabetic group. Moreover, the probability of having cardiovascular and cerebrovascular disease was also higher (P\u2009<\u20090.001) in the metformin and non-metformin groups. For the Luminal B (high ki67) and Luminal B (her-2/neu +) subgroups, there was a higher proportion of obese patients in the metformin and non-metformin groups (P\u2009<\u20090.001). In terms of clinical characteristics, for the Luminal B (high ki67) subtype, the proportion of patients with invasive ductal carcinoma was lower in the non-metformin group than in the other two groups (P\u2009=\u20090.001). In both the metformin and non-metformin groups, the proportion of T3/4 patients was higher (P\u2009<\u20090.001), the proportion of patients with lymph node metastasis was higher (P\u2009=\u20090.001), and the proportion of patients with vessel carcinoma embolus was higher (P\u2009=\u20090.001) compared with the nondiabetic group. In conclusion, compared with the metformin group, the non-metformin group had a poorer prognosis for all subtypes of luminal breast cancer. In the diabetic group, only patients with the Luminal B (high ki67) subtype exhibited a poorer prognosis. Therefore, different diabetes medication may have a different impact on the prognosis of different subtypes of luminal breast cancer.", 
    "genre": "research_article", 
    "id": "sg:pub.10.1007/s13277-013-1270-5", 
    "inLanguage": [
      "en"
    ], 
    "isAccessibleForFree": false, 
    "isPartOf": [
      {
        "id": "sg:journal.1091981", 
        "issn": [
          "1010-4283", 
          "1423-0380"
        ], 
        "name": "Tumor Biology", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "3", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "35"
      }
    ], 
    "name": "Clinical pathological characteristics and prognostic analysis of diabetic women with luminal subtype breast cancer", 
    "pagination": "2035-2045", 
    "productId": [
      {
        "name": "readcube_id", 
        "type": "PropertyValue", 
        "value": [
          "e824a8d9e3a8fdc13a9ac3459c557916f407db8bc30af4978e6b34579948ab02"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "24096546"
        ]
      }, 
      {
        "name": "nlm_unique_id", 
        "type": "PropertyValue", 
        "value": [
          "8409922"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/s13277-013-1270-5"
        ]
      }, 
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1048730426"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/s13277-013-1270-5", 
      "https://app.dimensions.ai/details/publication/pub.1048730426"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2019-04-10T18:23", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-uberresearch-data-dimensions-target-20181106-alternative/cleanup/v134/2549eaecd7973599484d7c17b260dba0a4ecb94b/merge/v9/a6c9fde33151104705d4d7ff012ea9563521a3ce/jats-lookup/v90/0000000001_0000000264/records_8675_00000524.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "http://link.springer.com/10.1007%2Fs13277-013-1270-5"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s13277-013-1270-5'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s13277-013-1270-5'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s13277-013-1270-5'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s13277-013-1270-5'


 

This table displays all metadata directly associated to this object as RDF triples.

265 TRIPLES      21 PREDICATES      76 URIs      33 LITERALS      21 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/s13277-013-1270-5 schema:about N02776b9c258d4126bdb8641ab6c858e9
2 N0612d44895b3470ab2e25238b66c4ca9
3 N0e137431d4904ec0892e69f54e01ec5e
4 N371da8e0076f43018de52e6884d83634
5 N80ea704bf2854f73b31a0f5495000d82
6 N873240a49024483884a09f785b7c27ff
7 N9809749b8aad437888e7994ded32630d
8 Naf533958a99a4ecfb2062da065f63887
9 Nb597d1177c3b45ad881cafab615b175d
10 Nbdf81cca3fd247b0b750e2d88ae54dd7
11 Nc21cdf8e0a8c483d866a7482de721f77
12 Nfd338a1f0bc84b918669e4c52380dd29
13 anzsrc-for:11
14 anzsrc-for:1112
15 schema:author N62c0192f2e114afa9c0e88ee36013967
16 schema:citation sg:pub.10.1007/s10549-010-0990-0
17 sg:pub.10.1007/s10549-012-2339-3
18 sg:pub.10.1007/s10552-012-0057-0
19 sg:pub.10.1007/s10911-008-9097-1
20 sg:pub.10.1007/s11670-012-0279-4
21 sg:pub.10.1007/s12032-011-0109-4
22 sg:pub.10.1038/nrc3215
23 https://app.dimensions.ai/details/publication/pub.1078589901
24 https://app.dimensions.ai/details/publication/pub.1080781104
25 https://doi.org/10.1002/cncr.26439
26 https://doi.org/10.1016/j.diabres.2011.10.029
27 https://doi.org/10.1016/j.steroids.2011.02.041
28 https://doi.org/10.1016/s1535-6108(02)00055-7
29 https://doi.org/10.1056/nejmoa021423
30 https://doi.org/10.1073/pnas.1221055110
31 https://doi.org/10.1073/pnas.73.12.4536
32 https://doi.org/10.1093/annonc/mdr534
33 https://doi.org/10.1093/annonc/mdt224
34 https://doi.org/10.1111/j.1349-7006.2008.01053.x
35 https://doi.org/10.1111/j.1467-789x.2011.00917.x
36 https://doi.org/10.1111/j.1749-6632.2012.06750.x
37 https://doi.org/10.1126/science.1092952
38 https://doi.org/10.1146/annurev-nutr-071811-150713
39 https://doi.org/10.1158/0008-5472.can-07-2310
40 https://doi.org/10.1158/1940-6207.capr-08-0081
41 https://doi.org/10.1200/jco.2009.19.6410
42 https://doi.org/10.1200/jco.2009.27.3011
43 https://doi.org/10.1371/journal.pone.0051446
44 https://doi.org/10.1634/theoncologist.2010-0206
45 https://doi.org/10.1634/theoncologist.2011-0412
46 https://doi.org/10.2337/dc08-2175
47 https://doi.org/10.3978/j.issn.1000-9604.2012.11.03
48 https://doi.org/10.3978/j.issn.2072-1439.2012.10.17
49 https://doi.org/10.3978/j.issn.2072-1439.2013.05.24
50 https://doi.org/10.4161/cc.8.1.7499
51 schema:datePublished 2014-03
52 schema:datePublishedReg 2014-03-01
53 schema:description This study selected luminal-type breast cancer patients as the study subjects. The patients were divided into groups according to the presence of diabetes and the types of medication used, and the patients' clinicopathological characteristics and prognostic indicators were explored. A total of 5,785 patients with luminal-type breast cancer admitted to Tianjin Medical University Cancer Institute and Hospital between January 2002 and December 2006 were selected as the study subjects. The subjects included 680 breast cancer patients with diabetes and 5,105 breast cancer patients without diabetes. The patients were divided into Luminal A, Luminal B (high ki67), and Luminal B (her-2/neu+) subtypes. Each subtype was further divided into a metformin group, a non-metformin group, and a nondiabetic group. The research indicators included breast cancer mortality, age, body mass index (BMI), amenorrhea, the presence of cardiovascular and cerebrovascular disease, pathological stage, pathological type, lymph node involvement, vessel carcinoma embolus, and the chemotherapy and endocrine regimen. A Kaplan-Meier analysis was conducted to analyze the differences in breast cancer mortality rates among the groups. The Cox proportional hazard model was adopted to detect independent factors related to prognosis. Kaplan-Meier univariate analysis showed that for the Luminal A, Luminal B (high ki67), and Luminal B (her-2/neu+) subtypes, the cancer-specific mortality rates differed significantly among the metformin, non-metformin, and nondiabetic groups. The 5-year survival rates were 94%, 82%, and 91% (P = 0.002); 93.5%, 81%, and 89% (P < 0.001); and 84%, 77%, and 83% (P = 0.035) for the subtypes within each group, respectively. Cox regression multivariate analysis showed that compared with the metformin group, all three subtypes of the, the non-metformin group showed poorer prognosis (hazard ratio [HR], 3.579; 95% confidence interval [CI], 1.506-8.506 [P = 0.004]; HR, 3.232; 95% CI, 1.839-5.678 [P < 0.001]; HR, 2.034; 95% CI,1.019-4.059 [P = 0.044] for Luminal A, Luminal B (high ki67), and Luminal B (her-2/neu+, respectively). Compared with the metformin group, the diabetic group showed poorer prognosis only for the Luminal B (high ki67) subtype (HR, 1.762; 95% CI, 1.033-3.005 [P = 0.038]). In addition, for the Luminal A, Luminal B (high ki67), and Luminal B (her-2/neu+) subgroups, there was a higher proportion of elderly patients (P < 0.001) and postmenopausal patients (P < 0.001) in the metformin and non-metformin groups than in the nondiabetic group. Moreover, the probability of having cardiovascular and cerebrovascular disease was also higher (P < 0.001) in the metformin and non-metformin groups. For the Luminal B (high ki67) and Luminal B (her-2/neu +) subgroups, there was a higher proportion of obese patients in the metformin and non-metformin groups (P < 0.001). In terms of clinical characteristics, for the Luminal B (high ki67) subtype, the proportion of patients with invasive ductal carcinoma was lower in the non-metformin group than in the other two groups (P = 0.001). In both the metformin and non-metformin groups, the proportion of T3/4 patients was higher (P < 0.001), the proportion of patients with lymph node metastasis was higher (P = 0.001), and the proportion of patients with vessel carcinoma embolus was higher (P = 0.001) compared with the nondiabetic group. In conclusion, compared with the metformin group, the non-metformin group had a poorer prognosis for all subtypes of luminal breast cancer. In the diabetic group, only patients with the Luminal B (high ki67) subtype exhibited a poorer prognosis. Therefore, different diabetes medication may have a different impact on the prognosis of different subtypes of luminal breast cancer.
54 schema:genre research_article
55 schema:inLanguage en
56 schema:isAccessibleForFree false
57 schema:isPartOf N2b74a1f903f04b94a97de4082827fd43
58 Naaf2837b63fb4e6b9cab34b573b33a53
59 sg:journal.1091981
60 schema:name Clinical pathological characteristics and prognostic analysis of diabetic women with luminal subtype breast cancer
61 schema:pagination 2035-2045
62 schema:productId N23c37fb1a74f4e49a5645ddd77de24d1
63 N5d1bd644a841436f878496f33f96df11
64 N6d4fa7f37fb0470cb4a1d6f3eeeaad20
65 N9eb624ea43544ae98c57053ce8d21868
66 Ne660f72f3eef4c56bd9d53e2d92ca5e6
67 schema:sameAs https://app.dimensions.ai/details/publication/pub.1048730426
68 https://doi.org/10.1007/s13277-013-1270-5
69 schema:sdDatePublished 2019-04-10T18:23
70 schema:sdLicense https://scigraph.springernature.com/explorer/license/
71 schema:sdPublisher N0b646abfa78e4be5b501a723a39c6d82
72 schema:url http://link.springer.com/10.1007%2Fs13277-013-1270-5
73 sgo:license sg:explorer/license/
74 sgo:sdDataset articles
75 rdf:type schema:ScholarlyArticle
76 N02776b9c258d4126bdb8641ab6c858e9 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
77 schema:name Proportional Hazards Models
78 rdf:type schema:DefinedTerm
79 N0612d44895b3470ab2e25238b66c4ca9 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
80 schema:name Kaplan-Meier Estimate
81 rdf:type schema:DefinedTerm
82 N0b646abfa78e4be5b501a723a39c6d82 schema:name Springer Nature - SN SciGraph project
83 rdf:type schema:Organization
84 N0e137431d4904ec0892e69f54e01ec5e schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
85 schema:name Aged
86 rdf:type schema:DefinedTerm
87 N23c37fb1a74f4e49a5645ddd77de24d1 schema:name readcube_id
88 schema:value e824a8d9e3a8fdc13a9ac3459c557916f407db8bc30af4978e6b34579948ab02
89 rdf:type schema:PropertyValue
90 N2b74a1f903f04b94a97de4082827fd43 schema:issueNumber 3
91 rdf:type schema:PublicationIssue
92 N371da8e0076f43018de52e6884d83634 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
93 schema:name Prognosis
94 rdf:type schema:DefinedTerm
95 N45b9c5fc2ba646b08e4c87f02ad6592f rdf:first sg:person.01240745050.60
96 rdf:rest rdf:nil
97 N47853cedcdc54890af42b9851f61b645 rdf:first sg:person.01250560002.28
98 rdf:rest Nb84eeebd63274d3f8c144dd413d7cbf0
99 N5d1bd644a841436f878496f33f96df11 schema:name nlm_unique_id
100 schema:value 8409922
101 rdf:type schema:PropertyValue
102 N618e5d6a69fb4225a5f84bc23e82f8e2 rdf:first sg:person.01207031500.94
103 rdf:rest N45b9c5fc2ba646b08e4c87f02ad6592f
104 N62c0192f2e114afa9c0e88ee36013967 rdf:first Nba69beb8bc9f4c6283c82e872604c300
105 rdf:rest N47853cedcdc54890af42b9851f61b645
106 N6d4fa7f37fb0470cb4a1d6f3eeeaad20 schema:name dimensions_id
107 schema:value pub.1048730426
108 rdf:type schema:PropertyValue
109 N80ea704bf2854f73b31a0f5495000d82 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
110 schema:name Diabetes Mellitus, Type 2
111 rdf:type schema:DefinedTerm
112 N873240a49024483884a09f785b7c27ff schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
113 schema:name Middle Aged
114 rdf:type schema:DefinedTerm
115 N9809749b8aad437888e7994ded32630d schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
116 schema:name Humans
117 rdf:type schema:DefinedTerm
118 N9eb624ea43544ae98c57053ce8d21868 schema:name doi
119 schema:value 10.1007/s13277-013-1270-5
120 rdf:type schema:PropertyValue
121 Naaf2837b63fb4e6b9cab34b573b33a53 schema:volumeNumber 35
122 rdf:type schema:PublicationVolume
123 Naf533958a99a4ecfb2062da065f63887 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
124 schema:name Hypoglycemic Agents
125 rdf:type schema:DefinedTerm
126 Nb597d1177c3b45ad881cafab615b175d schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
127 schema:name Metformin
128 rdf:type schema:DefinedTerm
129 Nb84eeebd63274d3f8c144dd413d7cbf0 rdf:first sg:person.01140643410.19
130 rdf:rest Ndd0dabfa811f493c86048d7a8518e0e0
131 Nba69beb8bc9f4c6283c82e872604c300 schema:affiliation Ne1030a655d1243a3a9d308a74bac8cfa
132 schema:familyName Xiao
133 schema:givenName Yuanting
134 rdf:type schema:Person
135 Nbdf81cca3fd247b0b750e2d88ae54dd7 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
136 schema:name Breast Neoplasms
137 rdf:type schema:DefinedTerm
138 Nc21cdf8e0a8c483d866a7482de721f77 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
139 schema:name Female
140 rdf:type schema:DefinedTerm
141 Ndd0dabfa811f493c86048d7a8518e0e0 rdf:first sg:person.0605031045.15
142 rdf:rest N618e5d6a69fb4225a5f84bc23e82f8e2
143 Ne1030a655d1243a3a9d308a74bac8cfa schema:name Surgical Department, Tianhe Hospital, Tianjin, China
144 rdf:type schema:Organization
145 Ne660f72f3eef4c56bd9d53e2d92ca5e6 schema:name pubmed_id
146 schema:value 24096546
147 rdf:type schema:PropertyValue
148 Nfd338a1f0bc84b918669e4c52380dd29 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
149 schema:name Adult
150 rdf:type schema:DefinedTerm
151 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
152 schema:name Medical and Health Sciences
153 rdf:type schema:DefinedTerm
154 anzsrc-for:1112 schema:inDefinedTermSet anzsrc-for:
155 schema:name Oncology and Carcinogenesis
156 rdf:type schema:DefinedTerm
157 sg:journal.1091981 schema:issn 1010-4283
158 1423-0380
159 schema:name Tumor Biology
160 rdf:type schema:Periodical
161 sg:person.01140643410.19 schema:affiliation https://www.grid.ac/institutes/grid.411918.4
162 schema:familyName Hou
163 schema:givenName Guofang
164 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01140643410.19
165 rdf:type schema:Person
166 sg:person.01207031500.94 schema:affiliation https://www.grid.ac/institutes/grid.411918.4
167 schema:familyName Hao
168 schema:givenName Xiaomeng
169 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01207031500.94
170 rdf:type schema:Person
171 sg:person.01240745050.60 schema:affiliation https://www.grid.ac/institutes/grid.411918.4
172 schema:familyName Zhang
173 schema:givenName Jin
174 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01240745050.60
175 rdf:type schema:Person
176 sg:person.01250560002.28 schema:affiliation https://www.grid.ac/institutes/grid.411918.4
177 schema:familyName Zhang
178 schema:givenName Sheng
179 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01250560002.28
180 rdf:type schema:Person
181 sg:person.0605031045.15 schema:affiliation https://www.grid.ac/institutes/grid.411918.4
182 schema:familyName Zhang
183 schema:givenName Xiaobei
184 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0605031045.15
185 rdf:type schema:Person
186 sg:pub.10.1007/s10549-010-0990-0 schema:sameAs https://app.dimensions.ai/details/publication/pub.1022806761
187 https://doi.org/10.1007/s10549-010-0990-0
188 rdf:type schema:CreativeWork
189 sg:pub.10.1007/s10549-012-2339-3 schema:sameAs https://app.dimensions.ai/details/publication/pub.1026751832
190 https://doi.org/10.1007/s10549-012-2339-3
191 rdf:type schema:CreativeWork
192 sg:pub.10.1007/s10552-012-0057-0 schema:sameAs https://app.dimensions.ai/details/publication/pub.1052280600
193 https://doi.org/10.1007/s10552-012-0057-0
194 rdf:type schema:CreativeWork
195 sg:pub.10.1007/s10911-008-9097-1 schema:sameAs https://app.dimensions.ai/details/publication/pub.1041148032
196 https://doi.org/10.1007/s10911-008-9097-1
197 rdf:type schema:CreativeWork
198 sg:pub.10.1007/s11670-012-0279-4 schema:sameAs https://app.dimensions.ai/details/publication/pub.1006388691
199 https://doi.org/10.1007/s11670-012-0279-4
200 rdf:type schema:CreativeWork
201 sg:pub.10.1007/s12032-011-0109-4 schema:sameAs https://app.dimensions.ai/details/publication/pub.1017161682
202 https://doi.org/10.1007/s12032-011-0109-4
203 rdf:type schema:CreativeWork
204 sg:pub.10.1038/nrc3215 schema:sameAs https://app.dimensions.ai/details/publication/pub.1007018896
205 https://doi.org/10.1038/nrc3215
206 rdf:type schema:CreativeWork
207 https://app.dimensions.ai/details/publication/pub.1078589901 schema:CreativeWork
208 https://app.dimensions.ai/details/publication/pub.1080781104 schema:CreativeWork
209 https://doi.org/10.1002/cncr.26439 schema:sameAs https://app.dimensions.ai/details/publication/pub.1007397922
210 rdf:type schema:CreativeWork
211 https://doi.org/10.1016/j.diabres.2011.10.029 schema:sameAs https://app.dimensions.ai/details/publication/pub.1001437964
212 rdf:type schema:CreativeWork
213 https://doi.org/10.1016/j.steroids.2011.02.041 schema:sameAs https://app.dimensions.ai/details/publication/pub.1006914612
214 rdf:type schema:CreativeWork
215 https://doi.org/10.1016/s1535-6108(02)00055-7 schema:sameAs https://app.dimensions.ai/details/publication/pub.1008635409
216 rdf:type schema:CreativeWork
217 https://doi.org/10.1056/nejmoa021423 schema:sameAs https://app.dimensions.ai/details/publication/pub.1041007839
218 rdf:type schema:CreativeWork
219 https://doi.org/10.1073/pnas.1221055110 schema:sameAs https://app.dimensions.ai/details/publication/pub.1015828667
220 rdf:type schema:CreativeWork
221 https://doi.org/10.1073/pnas.73.12.4536 schema:sameAs https://app.dimensions.ai/details/publication/pub.1037611161
222 rdf:type schema:CreativeWork
223 https://doi.org/10.1093/annonc/mdr534 schema:sameAs https://app.dimensions.ai/details/publication/pub.1011989210
224 rdf:type schema:CreativeWork
225 https://doi.org/10.1093/annonc/mdt224 schema:sameAs https://app.dimensions.ai/details/publication/pub.1042946743
226 rdf:type schema:CreativeWork
227 https://doi.org/10.1111/j.1349-7006.2008.01053.x schema:sameAs https://app.dimensions.ai/details/publication/pub.1008231897
228 rdf:type schema:CreativeWork
229 https://doi.org/10.1111/j.1467-789x.2011.00917.x schema:sameAs https://app.dimensions.ai/details/publication/pub.1026394639
230 rdf:type schema:CreativeWork
231 https://doi.org/10.1111/j.1749-6632.2012.06750.x schema:sameAs https://app.dimensions.ai/details/publication/pub.1048083141
232 rdf:type schema:CreativeWork
233 https://doi.org/10.1126/science.1092952 schema:sameAs https://app.dimensions.ai/details/publication/pub.1028575709
234 rdf:type schema:CreativeWork
235 https://doi.org/10.1146/annurev-nutr-071811-150713 schema:sameAs https://app.dimensions.ai/details/publication/pub.1037521943
236 rdf:type schema:CreativeWork
237 https://doi.org/10.1158/0008-5472.can-07-2310 schema:sameAs https://app.dimensions.ai/details/publication/pub.1027138181
238 rdf:type schema:CreativeWork
239 https://doi.org/10.1158/1940-6207.capr-08-0081 schema:sameAs https://app.dimensions.ai/details/publication/pub.1036462269
240 rdf:type schema:CreativeWork
241 https://doi.org/10.1200/jco.2009.19.6410 schema:sameAs https://app.dimensions.ai/details/publication/pub.1044475739
242 rdf:type schema:CreativeWork
243 https://doi.org/10.1200/jco.2009.27.3011 schema:sameAs https://app.dimensions.ai/details/publication/pub.1023678279
244 rdf:type schema:CreativeWork
245 https://doi.org/10.1371/journal.pone.0051446 schema:sameAs https://app.dimensions.ai/details/publication/pub.1042829178
246 rdf:type schema:CreativeWork
247 https://doi.org/10.1634/theoncologist.2010-0206 schema:sameAs https://app.dimensions.ai/details/publication/pub.1030560624
248 rdf:type schema:CreativeWork
249 https://doi.org/10.1634/theoncologist.2011-0412 schema:sameAs https://app.dimensions.ai/details/publication/pub.1029603059
250 rdf:type schema:CreativeWork
251 https://doi.org/10.2337/dc08-2175 schema:sameAs https://app.dimensions.ai/details/publication/pub.1028017606
252 rdf:type schema:CreativeWork
253 https://doi.org/10.3978/j.issn.1000-9604.2012.11.03 schema:sameAs https://app.dimensions.ai/details/publication/pub.1078680423
254 rdf:type schema:CreativeWork
255 https://doi.org/10.3978/j.issn.2072-1439.2012.10.17 schema:sameAs https://app.dimensions.ai/details/publication/pub.1078655931
256 rdf:type schema:CreativeWork
257 https://doi.org/10.3978/j.issn.2072-1439.2013.05.24 schema:sameAs https://app.dimensions.ai/details/publication/pub.1078751548
258 rdf:type schema:CreativeWork
259 https://doi.org/10.4161/cc.8.1.7499 schema:sameAs https://app.dimensions.ai/details/publication/pub.1072299977
260 rdf:type schema:CreativeWork
261 https://www.grid.ac/institutes/grid.411918.4 schema:alternateName Tianjin Medical University Cancer Institute and Hospital
262 schema:name 3rd Department of Breast Cancer, China Tianjin Breast Cancer Prevention, Treatment and Research Center, Tianjin Medical University Cancer Institute and Hospital; National Clinical Research Center of Cancer, West Beihuanhu Road, 300060, Tianjin, China
263 Key Laboratory of Breast Cancer Prevention and Therapy of Ministry of Education, Tianjin, China
264 Key Laboratory of Cancer Prevention and Therapy, Tianjin, China
265 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...